UBS AM’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-54,020
Closed -$117K 2692
2022
Q4
$117K Buy
54,020
+6,069
+13% +$50K ﹤0.01% 2485
2022
Q3
$574K Hold
47,951
﹤0.01% 2284
2022
Q2
$401K Hold
47,951
﹤0.01% 2383
2022
Q1
$416K Hold
47,951
﹤0.01% 2518
2021
Q4
$542K Sell
47,951
-1,791
-4% -$21.3K ﹤0.01% 2521
2021
Q3
$625K Hold
49,742
﹤0.01% 2406
2021
Q2
$404K Sell
49,742
-4,910
-9% -$42.6K ﹤0.01% 2594
2021
Q1
$506K Buy
54,652
+12,200
+29% +$123K ﹤0.01% 2387
2020
Q4
$411K Sell
42,452
-7,500
-15% -$73.9K ﹤0.01% 2352
2020
Q3
$620K Buy
49,952
+6,900
+16% +$91.5K ﹤0.01% 2037
2020
Q2
$560K Buy
43,052
+31,852
+284% +$401K ﹤0.01% 2070
2020
Q1
$114K Buy
+11,200
New +$146K ﹤0.01% 2383

Other funds holding GOSS

UBS AM's GOSS Position: Q1 2023 in Review

UBS AM sold out of Gossamer Bio (GOSS) in Q1 2023, closing a stake of 54,020 shares — an estimated $117K sold.

UBS AM first reported a position in GOSS in Q1 2020 and held it in 12 quarters. The position peaked at $625K in Q3 2021. 111 funds tracked by Wall St. Rank hold GOSS as of Q1 2023.

  • UBS AM reported no remaining Gossamer Bio position as of Q1 2023 after selling out during the quarter.
  • UBS AM sold 54,020 Gossamer Bio shares in Q1 2023, an estimated $117K.
  • UBS AM first reported a position in Gossamer Bio in Q1 2020 and held it in 12 quarters.
  • UBS AM's Gossamer Bio position peaked at $625K in Q3 2021.
  • 111 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.